Interrogation of Chronic Immunity and Interventional Approaches

Moderator(s)

• DC

  Daniela Cipolletta, PhD

  Sr.Director Immunology
  Immunology
  Seismic Therapeutic
  Watertown, Massachusetts, United States
• GM

  Gerald Morris

  University of California, San Diego

Presentations:

• 12:45 PM - 1:00 PM US ET

  Preliminary immunologic and clinical Phase 1b study outcomes from patients with ROSAH syndrome treated with the first-in-class ALPK1 inhibitor DF-003
  

  Speaker: Neil Solomons, MB BS – Drug Farm
• 1:00 PM - 1:15 PM US ET

  Host HLA Allelic Variation Shapes Risk of Severe SARS-CoV-2 Infection and Long COVID
  

  Author: Grace Kim, MS, PhD – Louisiana State University Health, New Orleans
• 1:15 PM - 1:30 PM US ET

  Discovery of potent, selective and insurmountable MRGPRX2 antagonists for mast cell-driven disorders
  

  Author: Yves Millet, PhD – Blueprint Medicines Corporation
• 1:30 PM - 1:45 PM US ET

  Engineered Nanobodies for Durable Tolerance in Allergic Asthma
  

  Author: Floris J. van Dalen, PhD – Boston Children's Hosp., Harvard Med. Sch.
• 1:45 PM - 2:00 PM US ET

  Persistent IL-17 Cytokine Patterns and Th17 Expansion Characterize Chronic Critical Illness after Severe Trauma
  

  Author: Caleb Y. Kim, BS – University of Minnesota, Twin Cities
• 2:00 PM - 2:15 PM US ET

  Targeting the Adenosine–Adenosine Deaminase-1 Axis to Restore HIV-Specific CD8⁺ T Cell Function
  

  Author: Arden O. Edgerton (she/her/hers) – Drexel University College of Medicine